Abstract
Background
Anthracycline therapy is limited by cardiotoxicity. Currently no diagnostic parameter is available allowing ubiquitous and reliable detection of preclinical anthracycline cardiomyopathy and prediction of prognosis.
Patients and methods
In 100 consecutive patients receiving anthracycline-based chemotherapy serial measurements of left ventricular systolic and diastolic function, Tei index (a Doppler echocardiographic parameter of global ventricular function), cardiac troponin T (cTnT) and NT-probrain natriuretic peptides (BNP) at baseline and during 1-year follow-up were performed.
Results
Mean ejection fraction (LVEF) significantly decreased immediately after completion of anthracycline therapy (mean dose 226.1 ± 8.3 mg/m2) und further declined during follow-up (65.9 ± 0.6% Vs. 61.6 ± 0.7%; P < 0.001), while mean E/A ratio decreased after 6 months (P = 0.05). No patient presented with cardiac symptoms. The Tei index increased after therapy in the majority of patients (78.8%) compared with pre-therapy values indicating myocardial alteration in more patients than previously recognized. cTnT levels did not exceed the upper limit of the normal range in any patient. Seven patients had low-level elevations of cTnT. Only one of these patients developed a concomitant decrease in LVEF. Mean N-terminal-pro-BNP (NT-proBNP) levels did not significantly change after anthracycline administration. However, in 13 patients (15.3%) a marked, transient increase of NT-proBNP was obtained after the first anthracycline cycle without cardiac dysfunction presumably due to altered cardiac loading conditions during chemotherapy.
Conclusion
Low to moderate doses of anthracyclines resulted in subclinical myocardial alteration in more patients than so far noticed. Clinical implications of increased Tei index remain to be determined in long-term. Our results do not support that assessment of cTnT or BNP levels may safely replace serial echocardiographic evaluation of systolic and diastolic function for the monitoring of anthracycline cardiotoxicity.
References
Auner HW, Tinchon C, Linkesch W, Tiran A, Quehenberger F, Link H, Sill H (2003) Prolonged monitoring of troponin T for the detection of anthracycline cardiotoxicity in adults with hematological malignancies. Ann Hematol 82:218–222
Belham M, Kruger A, Pritchard C (2006) The Tei index identifies a differential effect on left and right ventricular function with low-dose anthracycline chemotherapy. J Am Soc Echocardiogr 19:206–210
Brenner JS, Dolmetsch RE (2007) TrpC3 regulates hypertrophy-associated gene expression without affecting myocyte beating or cell size. PLoS ONE 2:e802
Cardinale D, Sandri MT, Martinoni A, Borghini E, Civelli M, Lamantia G, Cinieri S, Martinelli G, Fiorentini C, Cipolla CM (2002) Myocardial injury revealed by plasma troponin I in breast cancer treated with high-dose chemotherapy. Ann Oncol 13:710–715
Cardinale D, Sandri MT, Martinoni A, Tricca A, Civelli M, Lamantia G, Cinieri S, Martinelli G, Cipolla CM, Fiorentini C (2000) Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy. J Am Coll Cardiol 36:517–522
Daugaard G, Lassen U, Bie P, Pedersen EB, Jensen KT, Abildgaard U, Hesse B, Kjaer A (2005) Natriuretic peptides in the monitoring of anthracycline induced reduction in left ventricular ejection fraction. Eur J Heart Fail 7:87–93
Dujardin KS, Tei C, Yeo TC, Hodge DO, Rossi A, Seward JB (1998) Prognostic value of a Doppler index combining systolic and diastolic performance in idiopathic-dilated cardiomyopathy. Am J Cardiol 82:1071–1076
Efferth T, Giaisi M, Merling A, Krammer PH, Li-Weber M (2007) Artesunate induces ROS-mediated apoptosis in doxorubicin-resistant T leukemia cells. PLoS ONE 2:e693
Eidem BW, Sapp BG, Suarez CR, Cetta F (2001) Usefulness of the myocardial performance index for early detection of anthracycline-induced cardiotoxicity in children. Am J Cardiol 87:1120–1122, A1129
Ewer MS, Ali MK, Gibbs HR, Swafford J, Graff KL, Cangir A, Jaffe N, Thapar MK (1994) Cardiac diastolic function in pediatric patients receiving doxorubicin. Acta Oncol 33:645–649
Herman EH, Zhang J, Lipshultz SE, Rifai N, Chadwick D, Takeda K, Yu ZX, Ferrans VJ (1999) Correlation between serum levels of cardiac troponin-T and the severity of the chronic cardiomyopathy induced by doxorubicin. J Clin Oncol 17:2237–2243
Hullin R, Matthes J, von Vietinghoff S, Bodi I, Rubio M, D’Souza K, Friedrich Khan I, Rottlander D, Hoppe UC, Mohacsi P, Schmitteckert E, Gilsbach R, Bunemann M, Hein L, Schwartz A, Herzig S (2007) Increased expression of the auxiliary beta2-subunit of ventricular L-type Ca2+ channels leads to single-channel activity characteristic of heart failure. PLoS ONE 2:e292
Ishii M, Tsutsumi T, Himeno W, Eto G, Furui J, Hashino K, Sugahara Y, Muta H, Akagi T, Ando A, Eguchi H, Kato H (2000) Sequential evaluation of left ventricular myocardial performance in children after anthracycline therapy. Am J Cardiol 86:1279–1281, A1279
Keefe DL (2001) Anthracycline-induced cardiomyopathy. Semin Oncol 28(Suppl 12):2–7
Kilickap S, Barista I, Akgul E, Aytemir K, Aksoyek S, Aksoy S, Celik I, Kes S, Tekuzman G (2005) cTnT can be a useful marker for early detection of anthracycline cardiotoxicity. Ann Oncol 16:798–804
Kremer LC, Bastiaansen BA, Offringa M, Lam J, van Straalen JP, de Winter RJ, Voute PA (2002) Troponin T in the first 24 hours after the administration of chemotherapy and the detection of myocardial damage in children. Eur J Cancer 38:686–689
Kurz K, Voelker R, Zdunek D, Wergeland R, Hess G, Ivandic B, Katus H, Giannitsis E (2007) Effect of stress-induced reversible ischemia on serum concentrations of ischemia-modified albumin, natriuretic peptides and placental growth factor. Clin Res Cardiol 96:152–159
Latini R, Masson S, Anand IS, Missov E, Carlson M, Vago T, Angelici L, Barlera S, Parrinello G, Maggioni AP, Tognoni G, Cohn JN (2007) Prognostic value of very low plasma concentrations of troponin T in patients with stable chronic heart failure. Circulation 116:1242–1249
Lee BH, Goodenday LS, Muswick GJ, Yasnoff WA, Leighton RF, Skeel RT (1987) Alterations in left ventricular diastolic function with doxorubicin therapy. J Am Coll Cardiol 9:184–188
Lipshultz SE, Rifai N, Dalton VM, Levy DE, Silverman LB, Lipsitz SR, Colan SD, Asselin BL, Barr RD, Clavell LA, Hurwitz CA, Moghrabi A, Samson Y, Schorin MA, Gelber RD, Sallan SE (2004) The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. N Engl J Med 351:145–153
Lipshultz SE, Rifai N, Sallan SE, Lipsitz SR, Dalton V, Sacks DB, Ottlinger ME (1997) Predictive value of cardiac troponin T in pediatric patients at risk for myocardial injury. Circulation 96:2641–2648
Marchandise B, Schroeder E, Bosly A, Doyen C, Weynants P, Kremer R, Pouleur H (1989) Early detection of doxorubicin cardiotoxicity: interest of Doppler echocardiographic analysis of left ventricular filling dynamics. Am Heart J 118:92–98
Mason JW, Bristow MR, Billingham ME, Daniels JR (1978) Invasive and noninvasive methods of assessing adriamycin cardiotoxic effects in man: superiority of histopathologic assessment using endomyocardial biopsy. Cancer Treat Rep 62:857–864
Meinardi MT, van Veldhuisen DJ, Gietema JA, Dolsma WV, Boomsma F, van den Berg MP, Volkers C, Haaksma J, de Vries EG, Sleijfer DT, van der Graaf WT (2001) Prospective evaluation of early cardiac damage induced by epirubicin-containing adjuvant chemotherapy and locoregional radiotherapy in breast cancer patients. J Clin Oncol 19:2746–2753
Nousiainen T, Jantunen E, Vanninen E, Hartikainen J (2002) Early decline in left ventricular ejection fraction predicts doxorubicin cardiotoxicity in lymphoma patients. Br J Cancer 86:1697–1700
Pai VB, Nahata MC (2000) Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention. Drug Saf 22:263–302
Ribeiro I, Kawakami Y, Buscher D, Raya A, Rodriguez-Leon J, Morita M, Rodriguez Esteban C, Izpisua Belmonte JC (2007) Tbx2 and Tbx3 regulate the dynamics of cell proliferation during heart remodeling. PLoS ONE 2:e398
Roth HJ, Leithauser RM, Doppelmayr H, Doppelmayr M, Finkernagel H, von Duvillard SP, Korff S, Katus HA, Giannitsis E, Beneke R (2007) Cardiospecificity of the 3rd generation cardiac troponin T assay during and after a 216 km ultra-endurance marathon run in death valley. Clin Res Cardiol 96:359–364
Sahn DJ, DeMaria A, Kisslo J, Weyman A (1978) Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation 58:1072–1083
Sato T, Harada K, Tamura M, Watanabe A, Ishii M, Takada G (2001) Cardiorespiratory exercise capacity and its relation to a new Doppler index in children previously treated with anthracycline. J Am Soc Echocardiogr 14:256–263
Scharhag J, Herrmann M, Weissinger M, Herrmann W, Kindermann W (2007) N-terminal B-type natriuretic peptide concentrations are similarly increased by 30 minutes of moderate and brisk walking in patients with coronary artery disease. Clin Res Cardiol 96:218–226
Shan K, Lincoff AM, Young JB (1996) Anthracycline-induced cardiotoxicity. Ann Intern Med 125:47–58
Snowden JA, Hill GR, Hunt P, Carnoutsos S, Spearing RL, Espiner E, Hart DN (2000) Assessment of cardiotoxicity during haemopoietic stem cell transplantation with plasma brain natriuretic peptide. Bone Marrow Transplant 26:309–313
Steinherz LJ, Steinherz PG, Tan CT, Heller G, Murphy ML (1991) Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA 266:1672–1677
Stoddard MF, Seeger J, Liddell NE, Hadley TJ, Sullivan DM, Kupersmith J (1992) Prolongation of isovolumetric relaxation time as assessed by Doppler echocardiography predicts doxorubicin-induced systolic dysfunction in humans. J Am Coll Cardiol 20:62–69
Suzuki T, Hayashi D, Yamazaki T, Mizuno T, Kanda Y, Komuro I, Kurabayashi M, Yamaoki K, Mitani K, Hirai H, Nagai R, Yazaki Y (1998) Elevated B-type natriuretic peptide levels after anthracycline administration. Am Heart J 136:362–363
Swain SM, Whaley FS, Ewer MS (2003) Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 97:2869–2879
Tei C (1995) New non-invasive index for combined systolic and diastolic ventricular function. J Cardiol 26:135–136
Tei C, Nishimura RA, Seward JB, Tajik AJ (1997) Noninvasive Doppler-derived myocardial performance index: correlation with simultaneous measurements of cardiac catheterization measurements. Am J Soc Echocardiogr 10:169–178
Tikanoja T, Riikonen P, Perkkio M, Helenius T (1998) Serum N-terminal atrial natriuretic peptide (NT-ANP) in the cardiac follow-up in children with cancer. Med Pediatr Oncol 31:73–78
Tjeerdsma G, Meinardi MT, van Der Graaf WT, van Den Berg MP, Mulder NH, Crijns HJ, de Vries EG, van Veldhuisen DJ (1999) Early detection of anthracycline induced cardiotoxicity in asymptomatic patients with normal left ventricular systolic function: autonomic versus echocardiographic variables. Heart 81:419–423
Weber M, Kleine C, Keil E, Rau M, Berkowitsch A, Elsaesser A, Mitrovic V, Hamm C (2006) Release pattern of N-terminal pro B-type natriuretic peptide (NT-proBNP) in acute coronary syndromes. Clin Res Cardiol 95:270–280
Yeh ET, Tong AT, Lenihan DJ, Yusuf SW, Swafford J, Champion C, Durand JB, Gibbs H, Zafarmand AA, Ewer MS (2004) Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. Circulation 109:3122–3131
Yeo TC, Dujardin KS, Tei C, Mahoney DW, McGoon MD, Seward JB (1998) Value of a Doppler-derived index combining systolic and diastolic time intervals in predicting outcome in primary pulmonary hypertension. Am J Cardiol 81:1157–1161
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Dodos, F., Halbsguth, T., Erdmann, E. et al. Usefulness of myocardial performance index and biochemical markers for early detection of anthracycline-induced cardiotoxicity in adults. Clin Res Cardiol 97, 318–326 (2008). https://doi.org/10.1007/s00392-007-0633-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00392-007-0633-6